Download PDF
Thromb Haemost 1984; 51(01): 079-083
DOI: 10.1055/s-0038-1661025
Original Article
Schattauer GmbH Stuttgart

Neutralization of the Local Negative Charge Carried by Glycoprotein (GP)-Ib in Ristocetin-Induced Platelet Agglutination

K Tanoue
The Division of Cardiovascular Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
,
S M Jung
The Division of Cardiovascular Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
,
N Yamamoto
The Division of Cardiovascular Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
,
H Yamazaki
The Division of Cardiovascular Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
› Author Affiliations
Further Information

Publication History

Received 23 August 1983

Accepted 22 November 1983

Publication Date:
19 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Pretreatment of platelets with chymotrypsin dose-dependently decreased glycoprotein (GP)-Ib amounts as measured by SDS- PAGE, ristocetin-induced agglutination and platelet electrophoretic mobility (EPM). Decrease in platelet EPM in response to 0.75 mg/ml ristocetin alone were 7.0 ± 2.3 and 6.8 ± 4.3% (M ± S.E., n = 6) for control and chymotrypsin-treated platelets, respectively (p >0.2). Von Willebrand factor (vWF) alone had no effect on platelet EPM. However, in the presence of 0.75 mg/ml ristocetin, added vWF (2.9 μg/ml) caused a further 6.3 ± 3.8% decrease in control platelet EPM, but caused no significant decrease in the enzyme-treated platelets (p >0.05). In the presence of 0.3 mg/ml ristocetin, added vWF (2.9-14.5 μg/ml) caused a small but significant decrease in control platelet EPM, but caused no significant decrease in the enzyme-treated platelets.

These findings suggested that the GP-Ib carrying negative charge decreased by binding of vWF might facilitate a mutual approach of the GP-Ib molecules and bridge formation by vWF between different platelets.

Key Words

Platelet electrophoretic mobility (EPM) - Ristocetin-induced platelet agglutination - von Willebrand factor (vWF) - Glycoprotein (GP)–Ib - Chymotrypsin-treated platelets
 

  • References

  • 1 Seaman GV F. Surface potential and platelet aggregation. In: Platelets. Their Role in Haemostasis and Thrombosis. Brinkhous KM, Wright IS, Soulier JP, Roberts HR, Hinnom S. (eds) Schattauer-Verlag; Stuttgart: 1967. pp 53-68
    Google Scholar
  • 2 Kirby EP, Mills DC B. The interaction of bovine factor VIII with human platelets. J Clin Invest 1975; 56: 491-502
    CrossrefPubMedGoogle Scholar
  • 3 Kirby EP. Evans Blue: a specific inhibitor of factor VIII-induced platelet agglutination. Thrombos Diathes Haemorrh 1975; 34: 770-779
    PubMedGoogle Scholar
  • 4 Coller BS. The effects of ristocetin and von Willebrand factor on platelet electrophoretic mobility. J Clin Invest 1978; 61: 1168-1175
    CrossrefPubMedGoogle Scholar
  • 5 Ruan C, Tobelem G, McMichael AJ, Drouet L, Legrand Y, Degos L, Kieffer N, Lee H, Cane JP. Monoclonal antibody to human platelet glycoprotein-I. II. Effects on human platelet function. Br J Haematol 1981; 49: 511-519
    CrossrefPubMedGoogle Scholar
  • 6 Bernd MC, Phillips DR. Platelet membrane proteins: composition and receptor function. In: Platelet in biology and pathology. Gordon JL. (ed) North-Holland, Amsterdam: 1981. 2 43-75
    Google Scholar
  • 7 Caen JP, Nurden AR, Jeanneau C, Michel H, Tobelem G, Levy-Toledano S, Sultan Y, Valensi F, Bernhard J. Bemard-Soulier syndrome: a new glycoprotein abnormality. Its relationship with platelet adhesion to subendothelium and with the factor VIII von Willebrand protein. J Lab Clin Med 1976; 87: 586-596
    PubMedGoogle Scholar
  • 8 Weiss HJ, Tschopp TB, Baumgartner HR, Sussman I, Johnson MM, Egan JJ. Decreased adhesion of giant (Bemard-Soulier) platelets to subendothelium. Am J Med 1974; 57: 920-925
    CrossrefPubMedGoogle Scholar
  • 9 Howard MA, Hutton RA, Hardisty RM. Hereditary giant platelet syndrome: a disorder of a new aspect of platelet function. Br Med J 1973; 2: 586-588
    CrossrefPubMedGoogle Scholar
  • 10 Molnar J, Lorand L. Studies on apyrase. Arch Biochem Biophys 1961; 93: 353-363
    CrossrefPubMedGoogle Scholar
  • 11 Mustard JF, Perry DW, Kinlough-Rathbone RL, Packham MA. Preparation of suspensions of washed platelets from humans. Br J Haematol 1972; 22: 193-204
    CrossrefPubMedGoogle Scholar
  • 12 Kirby EP, Mills DC B. The effects of chymotrypsin and ADP on the binding site for bovine factor VIII on human platelets. Presented at Poster Session at the VIIIth ICTH Congress, Toronto, Canada, July 13-17, 1981 Thromb Haemostas 1981; 46: 304 (Abstr)
    PubMedGoogle Scholar
  • 13 Phillips DR. Effect of trypsin on the exposed polypeptides and glycoproteins of human platelet membranes. Biochemistry 1972; 11: 4582-4588
    CrossrefPubMedGoogle Scholar
  • 14 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 15 Olson JD, Brockway WJ, Fass DN, Bowie EJ, Mann KG. Purification of porcine and human risocetin-Willebrand factor. J Lab Clin Med 1977; 89: 1278-1294
    PubMedGoogle Scholar
  • 16 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 256-276
    PubMedGoogle Scholar
  • 17 Koutts J, Walsh PN, Plow EF, Fenton II JW, Bouma BN. Active release of human platelet factor VUI-related antigen by ADP, collagen and thrombin. J Clin Invest 1978; 62: 1225-1263
    PubMedGoogle Scholar
  • 18 Shimizu M, Iwaguchi T, Kikutani N, Motomiya T, Yamazaki H. A new method for measuring cell electrophoretic mobility. Proc Japan Acad 1979; 55: 418-423
    PubMedGoogle Scholar
  • 19 Yamazaki H, Tsukui R, Motomiya T, Jung SM, Sonoda M, Watanabe C, Ogino M, Miyagawa N. The increase of the electrophoretic mobility of platelets after laparotomy. Thromb Haemostas 1980; 44: 43-45
    PubMedGoogle Scholar
  • 20 Mester L, Szabados L, Bom GV, Micahl F. Changes in aggregation of platelets enriched in sialic acid. Nature New Biol 1972; 236: 213-214
    CrossrefPubMedGoogle Scholar
  • 21 Davis JW, Yue KT, Phillips PE. The effects of neuraminidase on platelet aggregation induced by ADP, norepinephrine, collagen or serotonin. Thrombos Diathes Haemorrh 1972; 28: 221-227
    PubMedGoogle Scholar
  • 22 Greenberg H, Packham MA, Cazenave JP, Reimers HJ, Mustard JF. Effects on platelet function of removal of platelet sialic add by neuraminidase. Lab Invest 1975; 32: 476-484
    PubMedGoogle Scholar
  • 23 Tanoue K, Isohisa I, Jung SM, Sakakibara C, Ariga S, Yamazaki H. Role of platelet surface negative charge in ristocetin-induced platelet agglutination (in Japanese with an English abstract). Blood Vessel 1982; 13: 543-546
    PubMedGoogle Scholar
  • 24 Jenkins CS, Phillips DR, Clemetson KJ, Meyer D, Larrieu M-J, Luscher EF. Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. J Clin Invest 1976; 57: 112-124
    CrossrefPubMedGoogle Scholar
  • 25 Okumura T, Jamieson GA. Platelet glycocalicin I., Orientation of glycoproteins of the human platelets surface. J Biol Chem 1976; 251: 5944-5949
    CrossrefPubMedGoogle Scholar
  • 26 Green D, Muller HP. Platelet binding of the von Willebrand factor. Thromb Haemostas 1978; 39: 689-694
    PubMedGoogle Scholar
  • 27 Schneider-Trip MD, Jenkins CS, Kahle LH, Sturk A, Ten CateJ. Studies on the mechanism of ristocetin-induced platelet aggregation: Binding of factor VIII to platelets. Br J Haematol 1979; 43: 99-112
    CrossrefPubMedGoogle Scholar
  • 28 McMichael AJ, Rust NA, Pilch JR, Sochynsky R, Morton J, Mason DY, Ruan C, Tobelem G, Caen J. Monoclonal antibody to human platelet glycoprotein I.I. Immunological studies. Br J Haematol 1981; 49: 501-509
    CrossrefPubMedGoogle Scholar
  • 29 Tam SW, Fenton II JW, Detwiler TC. Platelet thrombin receptors. Binding of α-thrombin is coupled to signal generation by a chymotrypsin-sensitive mechanism J Biol Chem 1980; 255: 6626-6632
    PubMedGoogle Scholar
  • 30 Jung SM, Kinoshita K, Tanoue K, Isohisa I, Yamazaki H. Role of surface negative charge in platelet function related to the hyperreactive state in estrogen-treated prostatic carcinoma. Thromb Haemostas 1982; 47: 203-209
    PubMedGoogle Scholar